How accurate is the apo-B data in determining risk compared with the gold standard?
Atherotech has developed a novel procedure to calculate apoB utilizing non-HDL-cholesterol along with lipoprotein density distribution using the patented VAP ultracentrifugation method. Atherotech has thoroughly validated this new procedure by comparing its calculated apoB with the gold standard* using serum from 1,797 patients. This comparison has yielded an excellent correlation coefficient (r = 0.96) with bias of only 3.8%. The long term (40 days) reproducibility of VAP apoB is 3.0% CV (coefficient of variance). The VAP apoB calculation work was accepted through a peer review process for presentation at 2007 Annual Meeting of American Association of Clinical Chemistry (AACC), and was subsequently published by AACC as an abstract.
Related Questions
- I want to achieve Gold standard compliance, but I don’t know what to send for some data elements in section E21 "Medical Device Data". What data is needed for this section?
- What is the gold standard and how do you determine which PTH test is best for determining bone status in the ESRD patient?
- How accurate is the apo-B data in determining risk compared with the gold standard?
